Australia markets closed
  • ALL ORDS

    7,105.70
    +56.30 (+0.80%)
     
  • AUD/USD

    0.7995
    +0.0032 (+0.41%)
     
  • ASX 200

    6,834.00
    +56.20 (+0.83%)
     
  • OIL

    63.32
    +0.10 (+0.16%)
     
  • GOLD

    1,791.70
    -6.20 (-0.34%)
     
  • BTC-AUD

    62,504.89
    -1,167.33 (-1.83%)
     
  • CMC Crypto 200

    1,000.80
    +6.14 (+0.62%)
     

Why Vir Biotechnology Stock Skyrocketed Today

Joe Tenebruso, The Motley Fool
·1-min read
Why Vir Biotechnology Stock Skyrocketed Today

Shares of Vir Biotechnology (NASDAQ: VIR) soared 74% on Tuesday after the immunology company released promising results from an early-stage study of its experimental antibody treatment for the hepatitis B virus (HBV). Preliminary data from Vir Biotechnology's phase 1 trial of its subcutaneously administered monoclonal antibody, VIR-3434, showed a marked reduction in HBV surface antigen levels in patients with chronic HBV infection. Better still, Vir Biotechnology engineered VIR-3434 to include a vaccinal mutation that could potentially allow it to function as a T cell vaccine against HBV.